August 1st 2025
An ongoing, open-label phase 1 study evaluating VT3989 in mesothelioma revealed positive early efficacy and encouraging safety with the agent.
ASCO 2015: Developmental Therapeutics Immunotherapy Poster Discussion
June 22nd 2015Not surprisingly, this was a very popular topic. I’m not sure why the ASCO planners didn’t anticipate this, because I had to wait a few minutes outside the door to even get in. At one point, it was standing room only!
Overcoming Drug Resistance in Lung Cancer
April 27th 2015Patients with lung cancer are increasingly receiving targeted therapies that induce complete disease remissions, but they can also develop resistance to these drugs. New efforts are now underway to discover and develop new options for patients experiencing drug resistance.